A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)

Autor: Zhao, Yuanyuan, Ma, Yuxiang, Fan, Yun, Zhou, Jianya, Yang, Nong, Yu, Qitao, Zhuang, Wu, Song, Weifeng, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Yu, Zhao, Hongyun, Zhang, Li
Zdroj: In Lung Cancer October 2023 184
Databáze: ScienceDirect
Externí odkaz: